Media Center

Elastrin Presents at MedTech - Elastrin made a strong impression at MedTech Ahead 2025 by presenting its latest advancements in medical technology.

Clemson University researchers published pre-clinical proof of reversing in lab animals the leading cause of cardiovascular events in chronic kidney disease, vascular calcification, by using advanced nanoparticle and antibody therapy. Results were published recently in Scientific Reports, a Nature publication. CKD is an epidemic globally and until now no one has reversed the calcification that kills most of its victims, especially those on dialysis. The team, led by Clems

Elastrin Therpapeutics has won the 2018 Xi´an International Entrepreneuship Competition held in Hamburg October 19, 2018 and was selected with four other startups from Germany to be invited to the finals. Chief Medical Officer Dr. med. Anne Thews delivered a presentation that convinced the jury consisting of various start-up and industry experts of the great potential our nanoparticle platform possesses for effective treatment of life-threatening diseases in over 40 Mio pa